## **Supplementary**

## Supplementary results

**Table S1:** Presentation and adverse in-hospital events of hospitalized patients with pulmonary

 embolism (PE) in Germany in stratified for the year of hospitalization and the COVID-19

 infection status.

Parameters	Hospitalized patients with	Hospitalized patients with	Hospitalized patients with
	PE 2019	PE 2020	PE 2020
		without COVID-19	with COVID-19
	(n=98,485)	(n=94,356)	(n=3,362)
Case-fatality rate	12,470 (12.7%)	11,795 (12.5%)	964 (28.7%)
Resuscitation	5,564 (5.6%)	5,115 (5.4%)	275 (8.2%)
Shock	5,214 (5.3%)	5,115 (5.4%)	453 (13.5%)
Systemic thrombolysis	3,917 (4.0%)	3,810 (3.9%)	173 (5.1%)
RV-dysfunction	23,205 (23.6%)	21,947 (23.1%)	706 (21.0%)
Treatment on ICU	18,241 (18.5%)	17,527 (18.6%)	1,325 (39.4%)
Mechanical ventilation	4,569 (4.6%)	4,532 (4.8%)	638 (19.0%)
ARDS	786 (0.8%)	747 (0.8%)	760 (22.6%)
Pneumonia	26,115 (26.5%)	25,664 (27.2%)	2,835 (84.3%)
ECMO	551 (0.6%)	429 (0.5%)	153 (4.6%)
CT-Angiography	64,503 (65.5%)	64,021 (67.9%)	2,517 (74.9%)
Renal insufficiency	12,413 (12.6%)	11,589 (12.3%)	344 (10.2%)

<u>Abbreviations:</u> ARDS, Acute respiratory distress syndrome; CT= Computed tomography; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit;

**Table S2**: Associations of patients' characteristics, comorbidities and adverse events with

 pulmonary embolism in patients with confirmed COVID-19 infection (univariable and

 multivariable logistic regression models).

	All in-hospital patients with COVID-19 infection				
	(n=176,137; 3362 patients had diagnosis of PE [1.9%])				
	Univariate		Multivariate		
			(adjusted for age, sex,	cancer, coronary	
	artery disease, heart failure, COPD,			ailure, COPD,	
	arterial hypertension, renal insufficiency,			enal insufficiency,	
			diabetes mellitus, atrial fibrillation, pAVK		
			and hyperlipidemia)		
Parameters	OR (95% CI)	P-value	OR (95% CI)	P-value	
Age ≥ 70	0.903 (0.844-0.967)	0.004	1.029 (0.952-1.112)	0.468	
Male Sex	1.208 (1.115-1.376)	<0.001	1.349 (1.205-1.497)	<0.001	
Obesity	1.759 (1.559-1.985)	<0.001	1.875 (1.657-2.121)	<0.001	
Comorbidities					
Coronary artery disease	0.735 (0.660-0.819)	<0.001	0.683 (0.608-0.767)	<0.001	
Cancer	1.288 (1.121-1.481)	<0.001	1.254 (1.090-1.442)	0.002	
PAD	0.790 (0.637-0.981)	0.033	0.838 (0.672-1-044)	0.116	
COPD	0.856 (0.741-0.988)	0.033	0.815 (0.704-0.944)	0.006	
Arterial hypertension	1.000 (0.934-1.070)	0.991	0.997 (0.926-1.073)	0.997	
Renal insufficiency	0.615 (0.549-0.688)	<0.001	0.553 (0.491-0.623)	<0.001	
Diabetes mellitus	0.996 (0.921-1.077)	0.925	0.989 (0.910-1.074)	0.790	
Atrial fibrillation	0.837 (0.764-0.917)	<0.001	0.736 (0.666-0.812)	<0.001	
Charlson Index	1.042 (1.030-1.054)	<0.001	1.095 (1.041-1.104)	<0.001	

<u>Abbreviations:</u> CI= Confidence interval; COPD= Chronic obstructive pulmonary disease; OR= Odds ratio; PAD= peripheral artery disease

Values in bold indicate that the difference is statistically significance at least in the multivariate regression model (p<0.05).

**Table S3**: Associations of COVID-19 with in-hospital mortality in patients with pulmonary

 embolism in 2020 (univariable and multivariable logistic regression models).

	All in-hospital patier	All in-hospital patients with pulmonary embolism in 2020 (n=97,718; 12,759 patients died [13.1%])				
	(n=97,718; 12,759 pa					
	Univariate		Multivariate			
			(adjusted for age, sex, cancer, coronary			
			artery disease, heart failure, COPD,			
			arterial hypertension, renal insufficiency,			
			diabetes mellitus, atrial fibrillation, pAVK			
			and Hyperlipidemia)			
Parameters	OR (95% CI)	P-value	OR (95% CI)	P-value		
COVID-19	2.814 (2.605-3.040)	<0.001	3.155 (2.910-3.420)	<0.001		

Abbreviations: CI= Confidence interval, OR= Odds ratio;

Values in bold indicate that the difference is statistically significance at least in the


multivariate regression model (p<0.05).

## Figure S1:

**Panel A** - Proportion of deaths (red line) in COVID-19 patients with PE (blue bars) stratified for age-decades of life

Panel B - Proportion of computed tomography pulmonary angiography (green line) in COVID-

19 patients with PE (blue bars) stratified for age-decades of life



**Figure S2:** Proportion of PE (blue line) in COVID-19 patients undergoing surgeries (orange bars) stratified for different kind of surgeries.

